2. Search Result
Search Result
Results for "

TEAD protein

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

9

Recombinant Proteins

2

Antibodies

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-134956
    VT104
    3 Publications Verification

    		 YAP Cancer
    VT104 is a potent and orally active YAP/TAZ inhibitor. VT104 prevents palmitoylation of endogenous TEAD1 and TEAD3 proteins. VT104 can be used in research of cancer .
    VT104
  • HY-138565
    K-975
    Maximum Cited Publications
    31 Publications Verification

    		 YAP Cancer
    K-975 is a potent, selective and orally active TEAD inhibitor, with a strong inhibitory effect against protein-protein interactions between YAP1/TAZ and TEAD. K-975 covalently binds to Cys359 located in the palmitate-binding pocket of TEAD via an acrylamide structure. K-975 exhibits antitumor activity on malignant pleural mesothelioma .
    K-975
  • HY-125016
    TT-10
    2 Publications Verification

    TAZ-K

    		 YAP Cardiovascular Disease Cancer
    TT-10 (TAZ-K) is an activator of YES-associated protein (YAP)-transcriptional enhancer factor domain (TEAD) activity. TT-10 can be used for the research of heart diseases accompanied by cardiomyocyte loss .
    TT-10
  • HY-125269
    TED-347
    10+ Cited Publications

    		 YAP Cancer
    TED-347 is a potent, irreversible, covalent and allosteric inhibitor at YAP-TEAD protein-protein interaction with an EC50 of 5.9 μM for TEAD4⋅Yap1 protein-protein interaction. TED-347 specifically and covalently bonds with Cys-367 within the central pocket of TEAD4 with a Ki of 10.3 μM. TED-347 blocks TEAD transcriptional activity and has antitumor activity .
    TED-347
  • HY-134955
    VT103
    5 Publications Verification

    		 YAP Cancer
    VT103, an analog of VT101, is an orally active and selective TEAD1 protein palmitoylation inhibitor. VT103 inhibits YAP/TAZ-TEAD promoted gene transcription, blocks TEAD auto-palmitoylation, and disrupts interaction between YAP/TAZ and TEAD. VT103 can be used for the research of cancer .
    VT103
  • HY-139330
    MGH-CP1
    1 Publications Verification

    		 Apoptosis Cancer
    MGH-CP1 is a potent and orally active TEAD2 and TEAD4 auto-palmitoylation inhibitor with IC50s of 710 nM and 672 nM, respectively. MGH-CP1 can decrease the palmitoylation levels of endogenous or ectopically expressed TEAD proteins in cells. MGH-CP1 can suppress Myc expression, inhibit epithelial over-proliferation, and induce apoptosis when together with Lats1/2 deletion .
    MGH-CP1
  • HY-168016
    PROTAC YAP degrader-1

    		PROTACs YAP Cancer
    PROTAC YAP degrader-1 is a VHL-recruiting PROTAC degrader (DC50=8.2 μM) and antiproliferative agent that targets YAP. PROTAC YAP degrader-1 recruits the E3 ligase VHL and binds to VHL to form a ternary complex containing YAP. PROTAC YAP degrader-1 inhibits the nuclear localization of YAP in cancer cells, reduces YAP/TEAD-mediated transcription, and induces TAZ protein degradation. PROTAC YAP degrader-1 reduces the oncogenic activity of YAP and exerts antiproliferative effects in the Huh7 xenograft mouse model. PROTAC YAP degrader-1 can be used for the research of hepatocellular carcinoma and mesothelioma .
    PROTAC YAP degrader-1
  • HY-163644
    VT-105

    		YAP Cancer
    VT-105 is a TEAD inhibitor and VT104 (HY-134956) analog. VT-105 binds to the central hydrophobic pocket of the TEAD3 protein. VT-105 can be used in the research of NF2-deficient malignant mesothelioma .
    VT-105
  • HY-151525A
    (R,S)-YAP-TEAD-IN-2

    		YAP Cancer
    (R,S)-YAP-TEAD-IN-2 is the racemic mixture of YAP-TEAD-IN-2 (HY-151525). YAP-TEAD-IN-2 (Compound 6) is a potent inhibitor of YAP-TEAD PPIs (protein-protein interaction) with an IC50 of 2.7 nM .
    (R,S)-YAP-TEAD-IN-2
  • HY-151525
    YAP-TEAD-IN-2

    		YAP Cancer
    YAP-TEAD-IN-2 (compound 6) is a potent YAP-TEAD PPI (protein-protein interaction) inhibitor with IC50 is 2.7 nM .
    YAP-TEAD-IN-2
  • HY-150256
    YTP-17

    		YAP Cancer
    YTP-17 is an orally active YAP-TEAD protein-protein interaction inhibitor with an IC50 of 4 nM. YTP-17 shows anti-tumor efficacy .
    YTP-17
  • HY-158400
    TEAD ligand 1

    		Ligands for Target Protein for PROTAC YAP Cancer
    TEAD ligand 1 is the ligand for target protein TEAD. TEAD ligand 1 is utilized for synthesis of PROTAC TEAD degrader-1 (HY-158342) .
    TEAD ligand 1
  • HY-157083
    mCMY020

    		YAP Cancer
    mCMY020 is a covalent inhibitor of TEAD. mCMY020 effectively reduces YAP (Yes-associated protein)-driven transcription and selectively slows the proliferation of Hippo-deficient cancer cells. mCMY020 can be used in cancer research .
    mCMY020
  • HY-186118
    TEAD ligand 6

    		Ligands for Target Protein for PROTAC YAP Neurological Disease Cancer
    TEAD ligand 6 is a TEAD ligand. TEAD ligand 6 serves as a ligand for target protein for PROTAC (Ligands for Target Protein for PROTAC) and is used to develop and design PROTAC-based TEAD degraders, such as KG-FP-003 (HY-186117). TEAD ligand 6 applies to glioblastoma research .
    TEAD ligand 6
  • HY-181538
    TEAD ligand 3

    		Ligands for Target Protein for PROTAC YAP Others
    TEAD ligand 3 (compound S20) is a TEAD ligand. As a target protein ligand, TEAD ligand 3 can be used in the synthesis of PROTAC TEAD1/IAP degrader-2 (HY-181537) .
    TEAD ligand 3
  • HY-181594
    PROTAC TEAD/IAP degrader-1

    		PROTACs SNIPERs YAP Cancer
    PROTAC TEAD/IAP degrader-1 is a TEAD/IAP PROTAC degrader. PROTAC TEAD/IAP degrader-1 is also a specific and Nongenetic inhibitor of apoptosis protein (IAP)-dependent protein eraser (SNIPERs). PROTAC TEAD/IAP degrader-1 recruits cIAP1 to form ternary complexes, induces ubiquitination, proteasomal TEAD1, TEAD4 degradation. PROTAC TEAD/IAP degrader-1 inhibits TEAD transcriptional activity, reduces CTGF expression, and reduces cell proliferation. PROTAC TEAD/IAP degrader-1 can be used for the research of mesothelioma .
    PROTAC TEAD/IAP degrader-1
  • HY-181536
    TEAD ligand 2

    		Ligands for Target Protein for PROTAC YAP Cancer
    TEAD ligand 2 is a target protein ligand that can be used for the synthesis of PROTACs, such as PROTAC TEAD1/IAP degrader-1 (HY-181534). PROTAC TEAD1/IAP degrader-1 is a potent TEAD1/IAP PROTAC degrader with anti-cancer activity .
    TEAD ligand 2
  • HY-186023
    TEAD ligand-Linker Conjugate 1

    		Target Protein Ligand-Linker Conjugates Cancer
    TEAD ligand-Linker Conjugate 1 is a synthetic target protein ligand-linker conjugate that can be used for the synthesis of PROTACs, such as PROTAC TEAD degrader-2 (HY-186021). PROTAC TEAD degrader-2 is a potent TEAD1 PROTAC degrader with anti-cancer activity .
    TEAD ligand-Linker Conjugate 1
  • HY-181607
    TEAD ligand-Linker Conjugate 3

    		YAP Others
    TEAD ligand-Linker Conjugate 3 (the blue structure + black structure of A536 in the literature) is a conjugate of a TEAD1-targeting ligand and a linker. TEAD ligand-Linker Conjugate 3 can be coupled with an IAP ligand (HY-181531) to form an IAP-recruiting bifunctional protein degrader (IPD) (HY-181594), also known as a SNIPER degrader. This TEAD SNIPER simultaneously binds to the TEAD1 palmitoylation pocket and the BIR3 domain of cIAP1 to form a ternary complex, efficiently inducing the ubiquitination and degradation of both TEAD1 and cIAP1 (DC50=110 nM, Dmax=51%; IC50=122 nM for cIAP1). TEAD ligand-Linker Conjugate 3 and its synthesized SENIPER molecule can be utilized in research on Hippo pathway dysregulation-related diseases, such as NF2-mutant tumors .
    TEAD ligand-Linker Conjugate 3
  • HY-181532
    IAP ligand 8

    		Ligands for E3 Ligase IAP Cancer
    IAP ligand 8 is an ASX-series, non-peptidic SMAC mimetic and IAP binder with high cell permeability. IAP ligand 8 selectively targets cIAP1-BIR3, XIAP-BIR2 (with a KD of 15.8 nM for both). IAP ligand 8 serves as an IAP ligand moiety to synthesize IAP-recruiting protein degrader (IPD) (HY-181590). This IPD simultaneously forms two ternary complexes, cIAP1-A538-TEAD1 and XIAP-A538-TEAD1, and efficiently degrades TEAD1 via a dual E3 recruitment mechanism, while inducing the autodegradation of cIAP1. IAP ligand 8 and its series of degraders are applicable to targeted research on Hippo pathway-dysregulated cancers such as NF2-mutant mesothelioma .
    IAP ligand 8
  • HY-181539
    TEAD ligand-Linker Conjugate 2

    		Target Protein Ligand-Linker Conjugates YAP Others
    TEAD ligand-Linker Conjugate 2 (compound S24) is a conjugate of TEAD‑targeted ligand and linker, which can be used for the synthesis of PROTAC TEAD1/IAP degrader-2 (HY-181537) .
    TEAD ligand-Linker Conjugate 2
  • HY-181533
    IAP ligand 9

    		Ligands for E3 Ligase IAP Cancer
    IAP ligand 9 is an ASX-series, non-peptidic SMAC mimetic and IAP binder with high cell permeability. IAP ligand 9 selectively targets cIAP1-BIR3, XIAP-BIR3, exhibits extremely weak binding affinity for XIAP-BIR2, with a KD of 100 nM for cIAP1-BIR3 and 10 nM for XIAP-BIR2. IAP ligand 9 can be used to synthesize IAP-recruiting protein degraders (IPD), and can calibrate the cell permeability and cellular-level target binding assays of the IPD molecule SNIPER (TEAD)-1 (HY-181607). IAP ligand 9 and its series of degraders can be used in the research of solid tumors such as malignant pleural mesothelioma associated with abnormal activation of the Hippo pathway .
    IAP ligand 9
  • HY-182672
    VT101

    		YAP Cancer
    VT101 is a TEAD inhibitor with an IC50 of 454 nM. VT101 is applicable for cancer research .
    VT101

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: